The GLP-1 class has grown steadily, and as of 2026, several FDA-approved glucagon-like peptide-1 receptor agonists are in routine clinical use for type 2 diabetes, chronic weight management, and cardiovascular risk reduction. These GLP-1 updates summarize what is currently approved, what these drugs are used for, and what to expect clinically — not a news feed, but a working snapshot.
The Current GLP-1 Class at a Glance
A GLP-1 receptor agonist mimics the natural incretin hormone glucagon-like peptide-1. These medicines stimulate glucose-dependent insulin release, suppress inappropriate glucagon, slow gastric emptying, and reduce appetite through central pathways. The net clinical effect is lower fasting and post-meal glucose and, for most patients, modest to substantial weight loss.
As of 2026, the FDA-approved injectable GLP-1 agents include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon). Oral semaglutide (Rybelsus) remains the only approved oral GLP-1 tablet. Tirzepatide (Mounjaro, Zepbound) is technically a dual GIP/GLP-1 receptor co-agonist but is commonly discussed alongside the GLP-1 class because of overlapping pharmacology.
Approved Indications
Indications vary by agent, and a brand approved for diabetes is not automatically approved for weight loss (and vice versa). Always confirm the exact indication on the current FDA label.
- Type 2 diabetes: Ozempic, Trulicity, Victoza, Bydureon, Byetta, Rybelsus, and Mounjaro carry type 2 diabetes indications.
- Chronic weight management: Wegovy (semaglutide) and Zepbound (tirzepatide) are approved for adults with obesity or overweight plus a weight-related comorbidity. Saxenda (liraglutide) carries a similar weight-management indication.
- Cardiovascular risk reduction: Several agents, including semaglutide and liraglutide formulations, have FDA-approved indications to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Clinical Benefits Observed in Trials
Pivotal trials for GLP-1 and GIP/GLP-1 agents have consistently shown meaningful A1C reductions and clinically significant weight loss, with tirzepatide generally producing the largest effect sizes. Several agents have also demonstrated cardiovascular and renal benefits in high-risk populations, which is why major guidelines now recommend GLP-1 therapy early in selected patients with type 2 diabetes who have atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.
If you are exploring whether these benefits apply to your situation, start with a full metabolic workup — your clinician can interpret your A1C levels alongside kidney function, lipids, and cardiovascular history before any prescription is considered.
FDA-Approved GLP-1 Agents: Quick Reference Table
| Generic Name | Brand(s) | Route | Primary Approved Use |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | SC weekly / oral daily | T2D, weight management, CV risk reduction |
| Liraglutide | Victoza, Saxenda | SC daily | T2D, weight management |
| Dulaglutide | Trulicity | SC weekly | T2D, CV risk reduction |
| Exenatide | Byetta, Bydureon BCise | SC twice daily / weekly | Type 2 diabetes |
| Tirzepatide (GIP/GLP-1) | Mounjaro, Zepbound | SC weekly | T2D, weight management |
Common and Serious Side Effects
Across the class, gastrointestinal effects dominate the adverse-event profile. According to FDA labeling, the most frequently reported effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite. These are usually dose-related and tend to diminish as the body adapts, especially with gradual titration managed by a clinician.
Less common but clinically important risks include pancreatitis, gallbladder disease, acute kidney injury from dehydration, injection-site reactions, and hypoglycemia when combined with insulin or sulfonylureas. The class carries a boxed warning regarding thyroid C-cell tumors based on rodent studies; human risk is unconfirmed, but these drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
Where GLP-1 Therapy Fits in Overall Treatment
Guidelines from the American Diabetes Association continue to position GLP-1 receptor agonists as a preferred add-on, and sometimes first-line injectable, for adults with type 2 diabetes who have cardiovascular disease, chronic kidney disease, or a strong need for weight loss. They are not a substitute for lifestyle change. A structured approach to prediabetes and diabetes treatment, plus meaningful improvements in diet and nutrition, remains the foundation on top of which medications work best.
What These Updates Do Not Cover
This overview deliberately avoids specific dose numbers, titration schedules, and injection technique. Those are decisions a clinician individualizes based on kidney function, other medicines, prior GI tolerance, pregnancy status, and treatment goals. Compounded versions sold outside the regulated supply chain are also outside the scope of FDA-approved GLP-1 updates and carry their own safety concerns the FDA has publicly flagged.
Medical Disclaimer
This article is for educational purposes only and is not medical advice. It is not a substitute for diagnosis, treatment, or guidance from a licensed healthcare professional. Always consult your doctor before starting, stopping, or changing any medication, including GLP-1 receptor agonists.
The Bottom Line
The 2026 GLP-1 class is broader and better characterized than it was even a few years ago, with multiple FDA-approved agents across diabetes, weight management, and cardiovascular indications. Benefits are real, side effects are manageable for most people with clinician supervision, and no single product is right for everyone. Bring this overview to a visit with your own doctor, and treat any specific dosing information only from a licensed prescriber.
